首页> ESMO open> Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.

Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.

导出 LinkOut

翻译打印收藏纠错

第一作者： E M,Ruggeri

第一单位： Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy.

作者： E M,Ruggeri ^[1] ; F,Nelli ^[2] ; A,Fabbri ^[1] ; A,Onorato ^[1] ; D,Giannarelli ^[3] ; J R,Giron Berrios ^[1] ; A,Virtuoso ^[1] ; E,Marrucci ^[1] ; M,Mazzotta ^[1] ; M,Schirripa ^[1] ; V,Panichi ^[4] ; G,Pessina ^[5] ; C,Signorelli ^[1] ; M G,Chilelli ^[1] ; F,Primi ^[1] ; F,Natoni ^[5] ; S,Fazio ^[5] ; M A,Silvestri ^[4]

作者单位： Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy. ^[1] Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy. Electronic address: fabrizio.nelli@asl.vt.it. ^[2] Clinical Trial Center, Biostatistics and Bioinformatics Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ^[3] Department of Oncology and Hematology, Microbiology and Virology Unit, Central Hospital of Belcolle, Viterbo, Italy. ^[4] Department of Oncology and Hematology, Molecular Biology and Covid Diagnostics, Central Hospital of Belcolle, Viterbo, Italy. ^[5]

关键词 COVID-19 vaccine antibody response cancer cytotoxic chemotherapy targeted therapy